Home
HelpTest Code CEASF Carcinoembryonic Antigen (CEA), Spinal Fluid
Reporting Name
Carcinoembryonic Ag (CEA), CSFUseful For
Detecting meningeal carcinomatosis and intradural or extradural infiltration
Differentiating brain parenchymal metastasis from adenocarcinoma or squamous-cell carcinoma
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
CSFSpecimen Required
Collection Container/Tube: Sterile vial
Submission Container/Tube: 13 x 75-mm tube
Specimen Volume: 0.5 mL
Specimen Minimum Volume
0.4 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| CSF | Refrigerated (preferred) | 14 days | |
| Frozen | 90 days | ||
| Ambient | 7 days |
Reference Values
<0.6 ng/mL
Tumor markers are not specific for malignancy, and values may vary by method.
Day(s) Performed
Monday through Saturday
Test Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82378
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| CEASF | Carcinoembryonic Ag (CEA), CSF | 2037-0 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| CEASF | Carcinoembryonic Ag (CEA), CSF | 2037-0 |
Clinical Information
Carcinoembryonic antigen (CEA) normally is present in cerebrospinal fluid (CSF) in very low concentrations. Elevations in serum CEA can cause passive transfer to CSF. Tumors of the brain, especially metastatic tumors, can elevate CSF CEA.
Interpretation
Increased values are seen in approximately 60% of patients with meningeal carcinomatosis.
Method Description
The Access carcinoembryonic antigen (CEA) assay is a 2-site immunoenzymatic sandwich assay using 2 mouse monoclonal anti-CEA antibodies (MAb) that react with different epitopes of CEA. A sample is added to a reaction vessel, along with the first anti-CEA MAb-alkaline phosphatase conjugate and the second anti-CEA MAb bound to paramagnetic particles. The incubation is followed by a magnetic separation and washing. The chemiluminescent substrate Lumi-Phos 530 is added to the vessel and light generated by the reaction is measured with a luminometer. The light production is proportional to the concentration of CEA in the sample. The amount of analyte in the sample is determined by means of a stored, multipoint calibrator curve.(Package insert: Access CEA, Beckman Coulter Inc; 2020)
Reject Due To
No specimen should be rejectedMethod Name
Immunoenzymatic Assay
Forms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.